Dr. Bérard (PhD) has cross-training in epidemiology and genetics from McGill University, Harvard Medical School, and Stanford University. She is Full Professor of Perinatal Epidemiology at the University of Montreal, Faculty of Pharmacy, and CHU Ste-Justine in Montreal; and Adjunct Professor at the Faculty of Medicine of the Université Claude Bernard in Lyon, France. Dr. Bérard holds a Canada Research Chair Tier 1 on Medications and Pregnancy; and University of Montreal’s Louis-Boivin research chair on «Medications, pregnancy and lactation». Anick Bérard is also Director of the Research Unit on Medications and Pregnancy at CHU Ste-Justine; Director of the Réseau québécois de recherche sur les médicaments of the Fonds de recherche du Québec – Santé (FRQ-S); Fellow of the International Society of Pharmacoepidemiology; and a voting member of the Teratology Society. Anick Bérard is the Principal Investigator of the i) Pan-Canadian CONCEPTION Study – COVID-19 and Pregnancy, ii) Quebec Pregnancy-Child Cohort, iii) Canadian Mother-Child Cohort (CAMCCO) Active Surveillance Initiative, iv) Canadian Mother-Child Collaborative Training Platform (CAMCCO-L), v) AMerican PREGNANcy/Child CohorT (AM-PREGNANT), and vi) French Nationwide Pregnancy Cohort, PregMed-France. Dr. Bérard has published over 500 scientific papers, abstracts and patents, and has obtained over 29 million dollars in funding from Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation (CFI), and FRQ-S as principal investigator. She recently received a Most Distinguished Scientist Award from the International Teratology Society for her work on antidepressants, maternal depression, and pregnancy.